loading
Madrigal Pharmaceuticals Inc stock is traded at $301.94, with a volume of 189.63K. It is up +2.42% in the last 24 hours and down -11.55% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$295.02
Open:
$297.84
24h Volume:
189.63K
Relative Volume:
0.52
Market Cap:
$7.09B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-12.02
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-5.90%
1M Performance:
-11.55%
6M Performance:
+48.42%
1Y Performance:
+41.54%
1-Day Range:
Value
$295.36
$310.00
1-Week Range:
Value
$276.20
$313.59
52-Week Range:
Value
$189.00
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
Name
Madrigal Pharmaceuticals Inc
Name
Phone
404-380-9263
Name
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
Employee
528
Name
Twitter
@MadrigalPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MDGL's Discussions on Twitter

Compare MDGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
302.08 7.09B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.22 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
584.26 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.69 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.17 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.65 26.16B 3.81B -644.79M -669.77M -6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Upgrade B. Riley Securities Neutral → Buy
Feb-27-25 Reiterated H.C. Wainwright Buy
Jun-28-24 Initiated Cantor Fitzgerald Neutral
Jun-11-24 Initiated Wolfe Research Outperform
Apr-22-24 Initiated BofA Securities Underperform
Mar-15-24 Upgrade B. Riley Securities Sell → Neutral
Mar-06-24 Initiated Citigroup Buy
Feb-26-24 Downgrade B. Riley Securities Neutral → Sell
Dec-20-22 Reiterated Oppenheimer Outperform
Dec-19-22 Reiterated H.C. Wainwright Buy
Dec-19-22 Reiterated Piper Sandler Overweight
Dec-19-22 Upgrade Raymond James Underperform → Mkt Perform
Jul-08-22 Downgrade B. Riley Securities Buy → Neutral
Oct-07-21 Initiated Jefferies Buy
Aug-06-21 Upgrade BMO Capital Markets Market Perform → Outperform
May-20-21 Resumed Goldman Buy
Nov-24-20 Resumed Evercore ISI Outperform
Nov-06-20 Reiterated H.C. Wainwright Buy
Jul-31-20 Initiated Piper Sandler Overweight
Jun-05-20 Initiated BMO Capital Markets Market Perform
May-05-20 Initiated Chardan Capital Markets Buy
Jan-30-20 Initiated Canaccord Genuity Buy
Jan-09-20 Upgrade UBS Neutral → Buy
Nov-07-19 Reiterated H.C. Wainwright Buy
Jun-25-19 Initiated Stifel Hold
Jun-10-19 Upgrade B. Riley FBR Neutral → Buy
Feb-28-19 Reiterated H.C. Wainwright Buy
Feb-22-19 Initiated SVB Leerink Outperform
Jan-23-19 Initiated UBS Neutral
Dec-14-18 Initiated Wolfe Research Outperform
Dec-12-18 Initiated B. Riley FBR Neutral
Nov-19-18 Downgrade Raymond James Mkt Perform → Underperform
Nov-16-18 Upgrade Evercore ISI In-line → Outperform
Sep-04-18 Initiated Citigroup Buy
Aug-06-18 Downgrade Goldman Buy → Neutral
Jun-28-18 Initiated Raymond James Mkt Perform
View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

pulisher
Apr 20, 2025

Madrigal Pharmaceuticals to Announce Q1 2025 Results with Live Webcast - MSN

Apr 20, 2025
pulisher
Apr 20, 2025

Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 | MDGL Stock News - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 18, 2025
pulisher
Apr 18, 2025

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire

Apr 18, 2025
pulisher
Apr 18, 2025

Madrigal Pharmaceuticals announces executive transition By Investing.com - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

Madrigal Pharmaceuticals announces executive transition - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Madrigal Pharmaceuticals Announces Leadership Transition - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

(MDGL) Technical Data - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Madrigal founder Rebecca Taub to step back; firm hires successor from Novartis - The Business Journals

Apr 16, 2025
pulisher
Apr 16, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer - The Manila Times

Apr 16, 2025
pulisher
Apr 16, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca - GlobeNewswire

Apr 16, 2025
pulisher
Apr 08, 2025

Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN

Apr 08, 2025
pulisher
Apr 05, 2025

Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN

Apr 05, 2025
pulisher
Apr 01, 2025

Trend Tracker for (MDGL) - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Mar 29, 2025

Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus

Mar 29, 2025
pulisher
Mar 28, 2025

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? - Yahoo

Mar 28, 2025
pulisher
Mar 28, 2025

Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 25, 2025

Analysts Expect Breakeven For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Before Long - simplywall.st

Mar 25, 2025
pulisher
Mar 21, 2025

(MDGL) On The My Stocks Page - Stock Traders Daily

Mar 21, 2025
pulisher
Mar 20, 2025

EU health regulator clears use of AI tool in fatty liver disease trials - Reuters

Mar 20, 2025
pulisher
Mar 18, 2025

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 18, 2025
pulisher
Mar 15, 2025

15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 12, 2025

Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

How the (MDGL) price action is used to our Advantage - Stock Traders Daily

Mar 11, 2025
pulisher
Mar 11, 2025

Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz

Mar 11, 2025
pulisher
Mar 11, 2025

Madrigal Pharmaceuticals appoints new board member - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com

Mar 11, 2025
pulisher
Mar 10, 2025

Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com

Mar 09, 2025
pulisher
Mar 07, 2025

Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Boston Pharma Plays Catch Up To Akero, 89bio In MASH - insights.citeline.com

Mar 06, 2025

Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):